All In Biotech

Drug Trial Radar · NCT06585241

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

A Phase 3b/4, Open-label Study to Assess the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,144

Planned (sponsor's estimate)

Start

Sep 9, 2024

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
First posted
Sep 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Conditions

  • SARS-CoV-2

Interventions

  • mRNA-1273 Variant-containing FormulationBiological

    Sterile liquid for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. mRNA-1273.167, mRNA-1273.712, mRNA-1273.251, and mRNA-1273.261: Geometric Mean Value of Neutralizing Antibody Against COVID-19 VariantsTime frame: Up to Day 29
  2. mRNA-1273.167, mRNA-1273.712, mRNA-1273.251, and mRNA-1273.261: Geometric Mean Fold Rise of Neutralizing Antibody Against COVID-19 VariantsTime frame: Up to 28 days after last dose of study intervention
  3. mRNA-1273.251 and mRNA-1273.261: Seroresponse RateTime frame: Up to Day 29

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • CenExel

    Atlanta, Georgia · Recruiting

  • CenExel

    Decatur, Georgia · Recruiting

  • Velocity Clinical Research

    Baton Rouge, Louisiana · Recruiting

  • Velocity Clinical Research

    Gulfport, Mississippi · Recruiting

  • Velocity Clinical Research

    Omaha, Nebraska · Recruiting

  • Richard Bennett - Clinical Research Partners

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.